Grifols shifts to two-system plasma model to boost regional self-sufficiency

  • Grifols will shift to a two-system operating model, aligning U.S.-sourced plasma with U.S. demand, ROW plasma with Europe and other markets.
  • Operating platforms will move toward greater autonomy, with separate functions, upgraded controls, stronger compliance, and expanded financial reporting.
  • Dedicated Biopharma U.S. and Biopharma ROW commercial organizations will lead execution, with Felipe Palacios running U.S. operations, Thierry Heinrich leading ROW.
  • Plan targets lower reliance on higher-cost U.S. plasma for lower-priced international markets, aiming to lift resilience, profitability, and margins over time.
  • Grifols Egypt for Plasma Derivates will invest an additional EUR 180 million, targeting 1,000,000 liters collected in 2026, ramping to 3,000,000 liters by 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Grifols SA published the original content used to generate this news brief on July 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.